Comparison of Atorvastatin and Rosuvastatin in Reduction of Inflammatory Biomarkers in Patients with Acute Coronary Syndrome.

Cureus 2019 Jun 14;11(6):e4898. Epub 2019 Jun 14.

Internal Medicine, Liaquat University of Medical and Health Sciences, Jamshoro, PAK.

Introduction High-sensitivity C-reactive protein (hs-CRP) has emerged to be a very useful and reliable clinical marker of primary as well as secondary cardiovascular morbidity and mortality. Elevated hs-CRP contributes to underlying atherogenesis and worsens disease prognosis. Along with their lipid-lowering properties, statins also contribute to the alleviation of micro-inflammation and reduces pro-inflammatory markers. The aim of this study is to compare the effects of rosuvastatin and atorvastatin in lowering hs-CRP levels in statin-naive patients admitted with acute coronary syndrome (ACS). Methods In this prospective, open-label randomized trial, group A was given rosuvastatin 40 mg daily and group B was given atorvastatin 20 mg daily along with standard post-ACS therapy. Lipid profile (mg/dL), hs-CRP (mg/L) and erythrocyte sedimentation rate (ESR) (mm/Hr) were recorded and measured as the baseline (before starting therapy) and then again after four weeks. The data were analyzed using SPSS for Windows version 22.0 (IBM Corp., Armonk, NY). Results With four weeks of treatment, both group A and B showed statistically significant reduction in serum hs-CRP levels (p<0.0001). In group A, there was a mean 51% decrease in hs-CRP levels, and in group B, a 35% reduction was seen. Group A showed markedly low hs-CRP levels than group B after four weeks of therapy (18.46 ± 6.35 vs. 24.67 ± 8.45) (p<0.0001). Group A showed mean 16% decrease in ESR levels as compared to 14% decrease in group B. Group A showed lower ESR levels than group B after four weeks of therapy (19.59 ± 11.83 vs. 20.52 ± 12.13) (p<0.0001). Conclusion Rosuvastatin showed a 50% decrease and atorvastatin showed a 35% reduction in serum hs-CRP levels in statin-naive ACS patients. Rosuvastatin has a more effective role in reducing micro-inflammation in ACS patients.

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.4898DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6689481PMC
June 2019
1 Read

Publication Analysis

Top Keywords

acute coronary
8
hs-crp levels
8
coronary syndrome
8
hs-crp
5
open-label randomized
4
randomized trial
4
prospective open-label
4
methods prospective
4
syndrome acs
4
acs methods
4
trial group
4
group rosuvastatin
4
daily standard
4
standard post-acs
4
atorvastatin daily
4
group atorvastatin
4
rosuvastatin daily
4
daily group
4
admitted with acute
4
patients admitted with
4

Similar Publications